a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Company profile
Ticker
MGNX
Exchange
Website
CEO
Scott Koenig
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MGNX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
8 Apr 24
DEFA14A
Additional proxy soliciting materials
8 Apr 24
DEF 14A
Definitive proxy
8 Apr 24
8-K
Other Events
3 Apr 24
8-K
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
EFFECT
Notice of effectiveness
16 Nov 23
CORRESP
Correspondence with SEC
14 Nov 23
UPLOAD
Letter from SEC
10 Nov 23
S-3
Shelf registration
6 Nov 23
Transcripts
MGNX
Earnings call transcript
2023 Q4
7 Mar 24
MGNX
Earnings call transcript
2023 Q3
6 Nov 23
MGNX
Earnings call transcript
2023 Q2
9 Aug 23
MGNX
Earnings call transcript
2023 Q1
9 May 23
MGNX
Earnings call transcript
2022 Q4
15 Mar 23
MGNX
Earnings call transcript
2022 Q3
3 Nov 22
MGNX
Earnings call transcript
2022 Q2
9 Aug 22
MGNX
Earnings call transcript
2022 Q1
4 May 22
MGNX
Earnings call transcript
2021 Q4
25 Feb 22
MGNX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Jeffrey Stuart Peters
8 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Jeffrey Stuart Peters
8 Mar 24
4
Eric Blasius Risser
6 Mar 24
4
Thomas Spitznagel
6 Mar 24
4
James Karrels
6 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89.90 mm | 89.90 mm | 89.90 mm | 89.90 mm | 89.90 mm | 89.90 mm |
Cash burn (monthly) | 6.29 mm | (no burn) | 11.83 mm | 8.91 mm | 11.75 mm | 1.74 mm |
Cash used (since last report) | 41.77 mm | n/a | 78.63 mm | 59.19 mm | 78.06 mm | 11.54 mm |
Cash remaining | 48.13 mm | n/a | 11.27 mm | 30.71 mm | 11.84 mm | 78.36 mm |
Runway (months of cash) | 7.7 | n/a | 1.0 | 3.4 | 1.0 | 45.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 129 |
Opened positions | 13 |
Closed positions | 17 |
Increased positions | 45 |
Reduced positions | 46 |
13F shares | Current |
---|---|
Total value | 269.10 bn |
Total shares | 67.55 mm |
Total puts | 3.90 k |
Total calls | 16.80 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLVGF Bellevue | 9.80 mm | $45.68 bn |
BBBOF BB Biotech | 8.93 mm | $0.00 |
BLK Blackrock | 6.04 mm | $28.13 bn |
T. Rowe Price Investment Management | 5.49 mm | $25.62 bn |
Armistice Capital | 4.71 mm | $21.96 bn |
Vanguard | 4.41 mm | $20.57 bn |
Millennium Management | 2.04 mm | $9.50 bn |
Frazier Life Sciences Management | 1.80 mm | $8.40 bn |
Wasatch Advisors | 1.41 mm | $6.57 bn |
Acadian Asset Management | 1.37 mm | $6.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Apr 24 | Peters Jeffrey Stuart | Common Stock | Sell | Dispose S | No | Yes | 18.22 | 3,165 | 57.67 k | 0 |
4 Apr 24 | Peters Jeffrey Stuart | Common Stock | Sell | Dispose S | No | Yes | 17.74 | 5,351 | 94.93 k | 3,165 |
4 Apr 24 | Peters Jeffrey Stuart | Common Stock | Sell | Dispose S | No | Yes | 16.38 | 232 | 3.80 k | 8,516 |
4 Apr 24 | Peters Jeffrey Stuart | Common Stock | Sell | Dispose S | No | Yes | 15.51 | 147 | 2.28 k | 8,748 |
4 Apr 24 | Peters Jeffrey Stuart | Common Stock | Sell | Dispose S | No | Yes | 15.07 | 42,500 | 640.48 k | 8,895 |
4 Apr 24 | Peters Jeffrey Stuart | Common Stock | Option exercise | Acquire M | No | No | 4.82 | 42,500 | 204.85 k | 51,395 |
4 Apr 24 | Peters Jeffrey Stuart | Employee stock option Common Stock | Option exercise | Dispose M | No | Yes | 4.82 | 42,500 | 204.85 k | 127,500 |
6 Mar 24 | Peters Jeffrey Stuart | Common Stock | Sell | Dispose S | No | Yes | 21.5 | 19,625 | 421.94 k | 8,895 |
6 Mar 24 | Peters Jeffrey Stuart | Common Stock | Option exercise | Acquire M | No | No | 10.15 | 8,750 | 88.81 k | 28,520 |
6 Mar 24 | Peters Jeffrey Stuart | Common Stock | Option exercise | Acquire M | No | No | 11.5 | 10,875 | 125.06 k | 19,770 |
News
TD Cowen Upgrades Macrogenics to Buy
9 Apr 24
Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82%
5 Apr 24
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
4 Apr 24
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
4 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
4 Apr 24
Press releases
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
3 Apr 24
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
7 Mar 24
MacroGenics to Participate in Upcoming Investor Conferences
1 Mar 24
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
27 Feb 24
MacroGenics to Participate in Upcoming Investor Conference
2 Feb 24